SAN FRANCISCO, January 22, 2008 /PRNewswire/ -- Synosia Therapeutics 
today announced the successful completion of its first clinical trial, a 
proof-of-concept study that evaluated new therapeutic options for 
SYN-111 (rufinamide), a sodium channel blocker. Rufinamide was 
discovered and developed by Novartis and is currently marketed by Eisai 
in Europe as a drug to treat a form of epilepsy. This first trial was 
completed in less than seven months from design to final dosing and less 
than a year after the rights to rufinamide in mood disorders were 
obtained from Novartis in an exclusive licensing agreement.

http://www.therapeuticsdaily.com/news/article.cfm?contentvalue=507410&contenttype=newsarchive&channelID=30

www.peoplewho.org